Knocking out barriers to engineered cell activity
Abstract
Engineered T cell therapies are revolutionizing cancer treatment by achieving long-lasting remission in blood-related cancers, such as leukemia and lymphoma. These therapies involve removal of patient T cells, “reprogramming” them to attack cancer cells, and then transferring them back into the patient. Targeted gene inactivation (knockout) using CRISPR-Cas9 can enhance T cell activity (1, 2) and has the potential to expand cell therapy applications. Until now, it has been unknown whether CRISPR-Cas9–edited T cells would be tolerated and thrive once reinfused into a human. On page 1001 of this issue, Stadtmauer et al. (3) present data from a phase 1 clinical trial (designed to test safety and feasibility) on the first cancer patients treated with CRISPR-Cas9–modified T cells. The findings represent an important advance in the therapeutic application of gene editing and highlight the potential to accelerate development of cell-based therapies.
- Authors:
-
- Univ. of California, Berkeley, CA (United States). Howard Hughes Medical Institute
- Univ. of California, Berkeley, CA (United States). Howard Hughes Medical Institute, California Institute for Quantitative Biosciences (QB3), Innovative Genomics Institute; Lawrence Berkeley National Lab. (LBNL), Berkeley, CA (United States); Univ. of California, San Francisco, CA (United States). Gladstone Institutes
- Publication Date:
- Research Org.:
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, CA (United States)
- Sponsoring Org.:
- USDOE Office of Science (SC)
- OSTI Identifier:
- 1633261
- Grant/Contract Number:
- AC02-05CH11231
- Resource Type:
- Accepted Manuscript
- Journal Name:
- Science
- Additional Journal Information:
- Journal Volume: 367; Journal Issue: 6481; Journal ID: ISSN 0036-8075
- Publisher:
- AAAS
- Country of Publication:
- United States
- Language:
- English
- Subject:
- 60 APPLIED LIFE SCIENCES
Citation Formats
Hamilton, Jennifer R., and Doudna, Jennifer A. Knocking out barriers to engineered cell activity. United States: N. p., 2020.
Web. doi:10.1126/science.aba9844.
Hamilton, Jennifer R., & Doudna, Jennifer A. Knocking out barriers to engineered cell activity. United States. https://doi.org/10.1126/science.aba9844
Hamilton, Jennifer R., and Doudna, Jennifer A. Thu .
"Knocking out barriers to engineered cell activity". United States. https://doi.org/10.1126/science.aba9844. https://www.osti.gov/servlets/purl/1633261.
@article{osti_1633261,
title = {Knocking out barriers to engineered cell activity},
author = {Hamilton, Jennifer R. and Doudna, Jennifer A.},
abstractNote = {Engineered T cell therapies are revolutionizing cancer treatment by achieving long-lasting remission in blood-related cancers, such as leukemia and lymphoma. These therapies involve removal of patient T cells, “reprogramming” them to attack cancer cells, and then transferring them back into the patient. Targeted gene inactivation (knockout) using CRISPR-Cas9 can enhance T cell activity (1, 2) and has the potential to expand cell therapy applications. Until now, it has been unknown whether CRISPR-Cas9–edited T cells would be tolerated and thrive once reinfused into a human. On page 1001 of this issue, Stadtmauer et al. (3) present data from a phase 1 clinical trial (designed to test safety and feasibility) on the first cancer patients treated with CRISPR-Cas9–modified T cells. The findings represent an important advance in the therapeutic application of gene editing and highlight the potential to accelerate development of cell-based therapies.},
doi = {10.1126/science.aba9844},
journal = {Science},
number = 6481,
volume = 367,
place = {United States},
year = {Thu Feb 06 00:00:00 EST 2020},
month = {Thu Feb 06 00:00:00 EST 2020}
}
Free Publicly Available Full Text
Publisher's Version of Record
Other availability
Search WorldCat to find libraries that may hold this journal
Cited by: 7 works
Citation information provided by
Web of Science
Web of Science
Save to My Library
You must Sign In or Create an Account in order to save documents to your library.
Works referenced in this record:
Optimized RNP transfection for highly efficient CRISPR/Cas9-mediated gene knockout in primary T cells
journal, February 2018
- Seki, Akiko; Rutz, Sascha
- Journal of Experimental Medicine, Vol. 215, Issue 3
Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition
journal, November 2016
- Ren, Jiangtao; Liu, Xiaojun; Fang, Chongyun
- Clinical Cancer Research, Vol. 23, Issue 9
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
journal, February 2017
- Eyquem, Justin; Mansilla-Soto, Jorge; Giavridis, Theodoros
- Nature, Vol. 543, Issue 7643
CRISPR-engineered T cells in patients with refractory cancer
journal, February 2020
- Stadtmauer, Edward A.; Fraietta, Joseph A.; Davis, Megan M.
- Science, Vol. 367, Issue 6481
CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells
journal, December 2016
- Liu, Xiaojuan; Zhang, Yongping; Cheng, Chen
- Cell Research, Vol. 27, Issue 1
CAR T cell immunotherapy for human cancer
journal, March 2018
- June, Carl H.; O’Connor, Roddy S.; Kawalekar, Omkar U.
- Science, Vol. 359, Issue 6382
CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
journal, April 2017
- Rupp, Levi J.; Schumann, Kathrin; Roybal, Kole T.
- Scientific Reports, Vol. 7, Issue 1
Identification of preexisting adaptive immunity to Cas9 proteins in humans
journal, January 2019
- Charlesworth, Carsten T.; Deshpande, Priyanka S.; Dever, Daniel P.
- Nature Medicine, Vol. 25, Issue 2
Reprogramming human T cell function and specificity with non-viral genome targeting
journal, July 2018
- Roth, Theodore L.; Puig-Saus, Cristina; Yu, Ruby
- Nature, Vol. 559, Issue 7714
A Pilot Trial of the Combination of Transgenic NY-ESO-1–reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab
journal, December 2018
- Nowicki, Theodore S.; Berent-Maoz, Beata; Cheung-Lau, Gardenia
- Clinical Cancer Research, Vol. 25, Issue 7